

Special Issue

The Role of Hypoxia Inducible Factor (HIF) in Cancers

Message from the Guest Editor

Hypoxia being a consequence of rapid tumors proliferation that outgrows surrounding vasculature, is a common feature of most cancers, and current understanding of the underlying molecular interactions governing cancers cells' adaptation to this insult limits their therapeutic utility. The activation of cellular hypoxia signaling relies on the accumulation of transcriptionally functional complexes of hypoxia-inducible factors (HIF-1 and HIF-2 and HIF-3) that interact with hypoxic-response elements (HREs) in the promoters and enhancers of their numerous target genes and serve as master regulators of cancer growth, metabolism, survival as well as metastasis and invasiveness. Hence, approaches that exploit HIF-based signaling networks are an attractive strategy for the treatment of cancer, however, its utility in therapy has been limited in scope. For this Special Issue of *Cancers*, "The Role of Hypoxia Inducible Factors (HIFs) in Cancer", we encourage the submission of review and primary research articles that showcase the molecular mechanisms of HIFs signaling in the cancer cells as well as novel related therapeutic strategies.

Guest Editor

Dr. Rafal Bartoszewski

Department of Biophysics, Faculty of Biotechnology, University of Wrocław, Wrocław, Poland

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/120689

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)